Ioannis D. Kyrochristos

Dr. Ioannis D. Kyrochristos


Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications

18 November 2019 in Cancers
Verified
Journal Article
Open access
PDF file
IKIoannis D. Kyrochristos
Ioannis D. Kyrochristos
DZDemosthenes E. Ziogas
Demosthenes E. Ziogas
AGAnna Goussia
Anna Goussia
GGGeorgios K. GLANTZOUNIS
Georgios K. GLANTZOUNIS
Dimitrios RoukosDimitrios Roukos
Dimitrios Roukos
The increasing incidence combined with constant rates of early diagnosis and mortality of colorectal cancer (CRC) over the past decade worldwide, as well as minor overall survival improvements in the industrialized world, suggest the need to shift from conventional research and clinical practice to the innovative development of screening, predictive and therapeutic tools. Explosive integration of next-generation sequencing (NGS) systems into basic, translational and, more recently, basket trials is transforming biomedical and cancer research, aiming for substantial clinical implementation as well. Shifting from inter-patient tumor variability to the precise characterization of intra-tumor genetic, genomic and transcriptional heterogeneity (ITH) via multi-regional bulk tissue NGS and emerging single-cell transcriptomics, coupled with NGS of circulating cell-free DNA (cfDNA), unravels novel strategies for therapeutic response prediction and drug development. Remarkably, underway and future genomic/transcriptomic studies and trials exploring spatiotemporal clonal evolution represent most rational expectations to discover novel prognostic, predictive and therapeutic tools. This review describes latest advancements and future perspectives of integrated sequencing systems for genome and transcriptome exploration to overcome unmet research and clinical challenges towards Precision Oncology.


11 November 2018 in Medicinal Research Reviews
Verified
Journal Article
Closed access
PDF file
IKIoannis D. Kyrochristos
Ioannis D. Kyrochristos
DZDemosthenes E. Ziogas
Demosthenes E. Ziogas
Dimitrios RoukosDimitrios Roukos
Dimitrios Roukos

Verified
Journal Article
Open access
PDF file
IKIoannis D. Kyrochristos
Ioannis D. Kyrochristos
GGGeorgios K. GLANTZOUNIS
Georgios K. GLANTZOUNIS
DZDemosthenes E. Ziogas
Demosthenes E. Ziogas
JGJohn Gizas
John Gizas
DIMITRIOS SCHIZASDIMITRIOS SCHIZAS
DIMITRIOS SCHIZAS
Dimitrios RoukosDimitrios Roukos
Dimitrios Roukos
Hepatobiliary and pancreatic (HBP) cancers are associated with high cancer-related death rates. Surgery aiming for complete tumor resection (R0) remains the cornerstone of the treatment for HBP cancers. The current progress in the adjuvant treatment is quite slow, with gemcitabine chemotherapy available only for pancreatic ductal adenocarcinoma (PDA). In the advanced and metastatic setting, only two targeted drugs have been approved by the Food & Drug Administration (FDA), which are sorafenib for hepatocellular carcinoma and erlotinib for PDA. It is a pity that multiple Phase III randomized control trials testing the efficacy of targeted agents have negative results. Failure in the development of effective drugs probably reflects the poor understanding of genome-wide alterations and molecular mechanisms orchestrating therapeutic resistance and recurrence. In the post-ENCODE (Encyclopedia of DNA Elements) era, cancer is referred to as a highly heterogeneous and systemic disease of the genome. The unprecedented potential of next-generation sequencing (NGS) technologies to accurately identify genetic and genomic variations has attracted major research and clinical interest. The applications of NGS include targeted NGS with potential clinical implications, while whole-exome and whole-genome sequencing focus on the discovery of both novel cancer driver genes and therapeutic targets. These advances dictate new designs for clinical trials to validate biomarkers and drugs. This review discusses the findings of available NGS studies on HBP cancers and the limitations of genome sequencing analysis to translate genome-based biomarkers and drugs into patient care in the clinic.